Drug Profile
A 100
Alternative Names: A-100Latest Information Update: 11 Sep 2023
Price :
$50
*
At a glance
- Originator AfaSci
- Class Analgesics; Peptides; Small molecules
- Mechanism of Action G protein-coupled receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Inflammatory pain
Highest Development Phases
- Preclinical Inflammatory pain
Most Recent Events
- 11 Sep 2023 Preclinical development is ongoing in USA (AfaSci pipeline, September 2023)
- 28 Aug 2020 No recent reports of development identified for preclinical development in Inflammatory-pain in USA
- 22 Jul 2016 A 100 is available for licensing as of 22 Jul 2016. http://www.afasci.com/index.php/